Home » Posts tagged 'warrants'

Tag Archives: warrants

Advanced Oncotherapy (AVO) – Exercise of warrants and options and issue of shares

AVO1Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has agreed to issue 7,166,667 new ordinary shares  of 1p in the Company to Dr. Nick Plowman, Chairman of the Medical Advisory Board, pursuant to the exercise of warrants and options at prices between 1.1 pence and 5 pence.

Application will be made for the 7,166,667 new Ordinary Shares to be admitted to trading on AIM and it is expected that Admission will occur on or about 7 August 2015. The new Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.

Total voting rights

Following Admission, the Company’s enlarged issued share capital will comprise 1,418,328,375 Ordinary Shares, with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of Ordinary Shares in the Company with voting rights will be 1,418,328,375. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

For further information, please contact:

Advanced Oncotherapy Plc

www.avoplc.com

Sanjeev Pandya, CEO

Tel: +44 20 3617 8728

Nicolas Serandour, CFO

Westhouse Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Beaufort Securities (Joint Broker)

Saif Janjua / Jon Levinson

Tel: +44 20 7382 8300

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

 

Advanced Oncotherapy (AVO) – Exercise of Warrants and issue of Shares

AVO1Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has today issued 34,122,682 new ordinary shares of 1p in the Company at a price of 1.1 pence per New Share pursuant to the exercise of warrants by Brahma AG. The warrants were issued on 25 September 2013 to Brahma in accordance with the share purchase agreement for ADAM SA.  Mr. Alberto Colussi, directly or indirectly through his vehicle Brahma, now controls 19.35% of the Issued Capital of AVO.

Commenting on this, Nicolas Serandour, CFO, said“The exercise of these warrants shows the continued support and confidence of Brahma and the Colussi family which we greatly appreciate.”

Application has been made for the 34,122,682 Shares to be admitted to trading on AIM and it is expected that Admission will occur on or about 4 August 2015. The Shares will rank pari passu in all aspects with the existing ordinary shares of the Company.

Total voting rights

Following Admission, the Company’s enlarged issued share capital will comprise 1,411,161,708 ordinary shares, with voting rights. The Company does not hold any ordinary shares in treasury. Therefore the total number of ordinary shares in the Company with voting rights will be 1,411,161,708. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

For further information, please contact:

Advanced Oncotherapy Plc

www.avoplc.com

Sanjeev Pandya, CEO

Tel: +44 20 3617 8728

Nicolas Serandour, CFO

Westhouse Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Beaufort Securities (Joint Broker)

Saif Janjua / Jon Levinson

Tel: +44 20 7382 8300

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

 

Advanced Oncotherapy – Exercise of Warrants and Issue of Shares

AVO1Exercise of Warrants and Issue of Shares.

Issue of Shares

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has today issued 600,000 new ordinary shares of 1p in the Company at a subscription price of 8 pence per Ordinary Share to Dr Enrico Vanni, a non-executive director, in lieu of his non-executive director fee and fees in connection with his providing operational management support to the Company’s ADAM subsidiary.

Following this transaction, Dr Vanni now holds 13,050,000 Ordinary Shares representing 0.97% of the issued share capital of the Company.

Exercise of Warrants and Issue of Shares

The company further announces that it has today issued 16,400 new ordinary shares of 1p in the Company at a price of 6 pence per Further Share pursuant to the exercise of warrants.

Admission

Application has been made for the 600,000 New Ordinary Shares and the 16,400 Further Shares to be admitted to trading on AIM and it is expected that Admission will occur on 21 July 2015. The Shares will rank pari passu in all respect with the existing Shares of the Company.

Total voting rights

Following Admission, the Company’s enlarged issued share capital will comprise 1,377,039,026 Shares, with voting rights. The Company does not hold any Shares in treasury. Therefore the total number of Shares in the Company with voting rights will be 1,377,039,026. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

For further information, please contact:

Advanced Oncotherapy Plc

www.avoplc.com

Sanjeev Pandya, CEO

Tel: +44 20 3617 8728

Nicolas Serandour, CFO

Westhouse Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Beaufort Securities (Joint Broker)

Saif Janjua / Jon Levinson

Tel: +44 20 7382 8300

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

 

Advanced Oncotherapy – Exercise of Warrants and Issue of Shares and Warrants

Exercise of Warrants

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for treating cancer, announces that it has today issued 5,000,000 new ordinary shares at a subscription price of 1 penny each pursuant to the exercise of warrants.

Issue of Further Shares and Warrants

In accordance with the Supplemental Agreement with Brahma AG announced on 2 April 2015, the Company announces that it has today issued 3,737,169 new ordinary shares and 4,216,293 five year warrants. The Warrants are exercisable at a price of 8.25p per share. The issue of the Further Shares and Warrants fully completes the Company’s obligations under the Agreement.

Admission

Application has been made for the 5,000,000 Warrant Shares and the 3,737,169 Further Shares to be admitted to trading on AIM and it is expected that Admission will occur on 22 May 2015. The Shares will rank pari passu in all respect with the existing Shares of the Company.

Total voting rights

Following Admission, the Company’s enlarged issued share capital will comprise 1,347,922,626 Shares, with voting rights. The Company does not hold any Shares in treasury. Therefore the total number of Shares in the Company with voting rights will be 1,347,922,626. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

For further information, please contact:

Advanced Oncotherapy Plc
www.avoplc.com
Sanjeev Pandya, CEO
Tel: +44 20 3617 8728
Nicolas Serandour, CFO

Westhouse Securities (Nomad & Joint Broker)
Antonio Bossi / David Coaten
Tel: +44 20 7601 6100

Beaufort Securities (Joint Broker)
Saif Janjua / Jon Levinson
Tel: +44 20 7382 8300

Walbrook PR (Financial PR & IR)
Tel: +44 20 7933 8780 or avo@walbrookpr.com
Paul McManus / Anna Dunphy
Mob: +44 7980 541 893 / Mob: +44 7876 741 001

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.